

RIFM supports SenzaGen with new SEK 1.5m grant for non-animal photosensitization testing

Lund, May 10, 2022

SenzaGen will continue its collaboration with the Research Institute for Fragrance Materials (RIFM) on non-animal photosensitization testing. The new grant provided by RIFM will add SEK 1.5 million to SenzaGen's sales and is for testing chemicals with GARD® for photosensitization. The tests will be performed at SenzaGen's GLP-certified laboratory in Lund in the spring and summer of 2022.

Following successful initial evaluation in 2021, RIFM decided to test more ingredients with GARD@skin Dose-Response, which has been adapted to identify the dose levels at which a fragrance can induce skin allergies when exposed to sunlight (photosensitization).

"We are very proud to continue our collaboration with RIFM. RIFM's continued trust in us affirms their appreciation of the many application areas that our GARD® technology offers and can be adapted to. The need to measure the photosensitization risk is significant for product development companies in the cosmetics and chemicals industries, which are two of the industries we prioritize," says Peter Nählstedt, President and CEO of SenzaGen.

RIFM is an international scientific institute ensuring the safe use of fragrance ingredients in consumer products with an independent expert panel and a comprehensive library of chemicals. Both companies have collaborated on several projects since 2020 and look forward to jointly contributing to progress in terms of sustainability and ethics in the testing market.

"We were very excited by the preliminary results we saw with the GARD@skin Dose-Response adapted for photosensitization. Continuation of this work was the logical next step. Although it is rare, photosensitization is one of the critical human health endpoints RIFM evaluates and having a non-animal assay to assess for photosensitization is key," says Gretchen Ritacco, Principal Scientist, Phototoxicology at RIFM.

GARD@skin Dose-Response is a test that provides quantitative information on the concentration at which a substance causes allergy. In the RIFM project, the test materials are exposed to sunlight in one step to identify their photosensitization. The test enables companies in industries including cosmetics, pharmaceuticals and chemicals to identify the concentration of a substance at which it is safe for human use, which serves as a crucial basis for prioritization and decision-making in research and development. The test is an expanded application domain of GARD@skin, and it is one of the first of its kind on the market.

For more information, please contact:

Peter Nählstedt, President and CEO, SenzaGen AB

Email: peter.nahlstedt@senzagen.com | Mobile: +46 700-23 44 31

Gretchen Ritacco, Principal Scientist, Phototoxicology, RIFM

Email: gritacco@rifm.org | Phone: +1 201.689.8089 ext. 153



About RIFM

Established in 1966, the Research Institute for Fragrance Materials (RIFM) generates, analyzes, evaluates, and distributes data to provide a scientific basis for the safe use of fragrances. RIFM has compiled the most comprehensive, worldwide source of toxicology data, literature, and general information on fragrance and flavor raw materials. RIFM's Fragrance Ingredient Safety Assessment program draws from its comprehensive database of over 70,000 references and more than 135,000 human health and environmental studies.

RIFM assesses the safety of fragrance ingredients by the most current, internationally accepted guidelines—and has done so since its founding. The Expert Panel for Fragrance Safety, an independent, international team of researchers and academics with no ties to the fragrance industry, reviews all of RIFM's work before RIFM submits it for peer-reviewed publication in a reputable scientific journal. RIFM makes all of its published, peer-reviewed work—current and historical—available for free at fragrancematerialsafetyresource.elsevier.com.

About SenzaGen AB (publ)

SenzaGen aims to be a leader in non-animal toxicology testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and advisory and innovation services based on the latest technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the Company's Certified Adviser.

Attachments

[RIFM supports SenzaGen with new SEK 1.5m grant for non-animal photosensitization testing](#)